

国内版国际版

Microsoft Bing

Long-term response to avelumab and management of oligoprogre

Sign in

Add the Give with Bing extension

ALLIMAGESVIDEOS

29,300 ResultsAny time

Avelumab Maintenance Therapy for Advanced or Metastatic ...

<https://www.nejm.org/doi/10.1056/NEJMoa2002788>

Cited by: 56Author: Thomas Powles, Se Hoon Park, Eric Voog, Clau...Publish Year: 2020

Avelumab is an anti-PD-L1 antibody that has been approved in several countries for the treatment of locally advanced or metastatic urothelial carcinoma after disease progression during or after ...

Avelumab in Participants With Merkel Cell Carcinoma ...

<https://clinicaltrials.gov/ct2/show/NCT02155647>

Jun 04, 2014 · Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunoth...

Avelumab in patients with previously treated metastatic ...

<https://jitc.bmj.com/content/8/1/e000674>

Search Tools

Turn off Hover Translation (关闭取词)

https://cn.bing.com/?FORM=Z9FD1

Microsoft Bing

国内版 国际版

Long-term response to avelumab and management of oligoprogress

ALL IMAGES VIDEOS

20,500 Results Any time

Avelumab in Participants With Merkel Cell Carcinoma ...

<https://clinicaltrials.gov/ct2/show/NCT02155647>

Jun 04, 2014 Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020 May;9(1): pii: e000674. doi: 10.1136/jitc-2020-000674.

Metastatic Merkel cell carcinoma response to nivolumab ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0186-1>

Nov 15, 2016 Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis as a likely contributor to immune evasion in MCC. We report a case of a patient with metastatic MCC with a significant and durable response to nivolumab, a humanized ...

Cited by: 26 Author: Frances M. Walocko, Benjamin Y. Schai...

Publish Year: 2016

Merkel cell carcinoma and 18FDG PET-CT: A case report ...

<https://www.sciencedirect.com/science/article/pii/S0926125820301959>

Feb 01, 2021 - 1. Introduction. Merkel cell carcinoma is a rare primary neuroendocrine cancer that was first described by Toker in 1979 as trabecular neurocarcinoma. It arises predominantly in sun-exposed skin as

Chat with Bing


Am I the most talkative search engine?

Say something...

Merkel cell carcinoma

Medical Condition

A rare skin cancer that appears as a painless, flesh-colored or bluish-red nodule on the skin




A type of skin cancer characterized by flesh-colored nodules that occurs on the face, head or neck. It begins in the cells at the base of the uppermost layer of the skin (epidermis)

06-May-2021 02:32PM

Loading...

FAQ

 iThenticate®

63794_Auto_Edited.docx

Quotes Included
Bibliography Included
2%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 63794


Manuscript Type: CASE REPORT

Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report


Avelumab in unresectable Merkel cell carcinoma

Inês Leão, Joana Marinho, Telma Costa



Match Overview






激活 Windows
转到“设置”以激活 Windows。



PAGE 1 OF 11

Test-Only Report

国内版 国际版

Long-term response to avelumab and management of oligoprogress



ALL

IMAGES

VIDEOS

25,400 Results

Any time ▾

Avelumab for advanced Merkel cell carcinoma in the ...

<https://jtc.bmj.com/content/8/2/e001076> ▾

Sep 01, 2020 · Background **Merkel cell carcinoma** (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor **avelumab** has shown high **response** rates (RRs) and durable **responses** in patients with advanced MCC (aMCC) in clinical trials. To date, only results from clinical trials, patients treated in an expanded access program and ...

Cited by: 1

Author: Sonja Levy, Maureen J B Aarts, Ferry A L...

Publish Year: 2020

Avelumab in Participants With Merkel Cell Carcinoma ...

<https://clinicaltrials.gov/ct2/show/NCT02155647> ▾

Jun 04, 2014 · **Avelumab** in patients with previously treated metastatic **Merkel cell carcinoma**: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN **Merkel** 200 trial. J Immunother Cancer. 2020 May;8(1). pii: e000674. doi: 10.1136/jtc-2020-000674.

Avelumab in patients with previously treated metastatic ...

<https://jtc.bmj.com/content/8/1/e000674> ▾

May 01, 2020 · Background **Merkel cell carcinoma** (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, **avelumab** (anti-programmed death-ligand 1 (PD-L1)) became the first approved treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable **responses** in a subset of patients. Here, we report long-term efficacy and safety data and ...

Cited by: 15

Author: Sandra P D'Angelo, Sandra P D'Angelo, ...

Publish Year: 2020

Efficacy and Safety of First-line Avelumab Treatment in ...

<https://jamanetwork.com/journals/jamaoncology/fullarticle/2675910> ▾

Sep 13, 2018 · Importance **Merkel cell carcinoma** (MCC) is an aggressive skin cancer that is associated with poor survival outcomes in patients with distant metastatic disease. Results of part A of the JAVELIN **Merkel** 200 trial (**avelumab** in patients with **Merkel cell carcinoma**) showed that **avelumab**, an anti-programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy in second-line or later ...

Cited by: 227

Author: Sandra P. D'Angelo, Jeffery Russell, Céle...

Publish Year: 2018